CJC-1295 + Ipamorelin vs Ipamorelin

CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin is a dual-peptide formulation combining a growth hormone-releasing hormone (GHRH) analogue with a selective growth hormone secretagogue receptor (GHSR/ghrelin receptor) agonist. These two peptides operate through complementary mechanisms: CJC-1295 (without DAC) stimulates GH release by binding GHRH receptors on pituitary somatotrophs and amplifying the baseline GH pulse, while ipamorelin activates the ghrelin receptor to initiate a separate GH release signal. When used together, research indicates a synergistic amplification of GH pulsatility that exceeds the additive effects of either peptide alone. This synergy was characterized in studies examining GHRH-GHRP combined use, where combined studies produced GH peaks 2-3 times greater than single-agent studies (Bowers et al., Endocrinology). Ipamorelin is distinguished among ghrelin mimetics by its high selectivity for GH release without significantly elevating cortisol, prolactin, or ACTH levels, as demonstrated in clinical studies (Raun et al., European Journal of Endocrinology, 1998). CJC-1295 without DAC has a half-life of approximately 30 minutes, producing acute GH pulses rather than sustained elevation. Compared to GHRP-6, which broadly activates ghrelin receptors causing appetite stimulation, ipamorelin offers cleaner GH release profiles. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. This combination is widely studied by endocrinology research labs, sports medicine institutions, and body composition research centers investigating modulated GH secretagogue studies.

Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor). Its mechanism involves binding the ghrelin receptor on anterior pituitary somatotrophs to trigger calcium influx and GH granule exocytosis. What distinguishes ipamorelin from earlier ghrelin mimetics is its remarkable selectivity: clinical studies by Raun et al. (European Journal of Endocrinology, 1998) demonstrated that ipamorelin stimulates GH release in a concentration-dependent manner without significantly affecting cortisol, prolactin, FSH, LH, or TSH levels, even at high concentrations. This selectivity profile makes it one of the cleanest GH secretagogues available for research. In bone metabolism research, Anderson et al. (Bone, 2001) showed that ipamorelin use in ovariectomized rat models increased bone mineral content and bone formation markers, suggesting anabolic effects on skeletal tissue independent of IGF-1 elevation. The peptide has also been studied in post-operative recovery models, where it demonstrated prokinetic effects on gastric motility. Compared to GHRP-6 and GHRP-2, which also activate the ghrelin receptor but additionally stimulate appetite and affect cortisol/prolactin levels, ipamorelin provides a more isolated GH response. Store lyophilized powder at -20C; reconstitute with bacteriostatic water and refrigerate at 2-8C for up to 28 days. Ipamorelin is investigated by endocrinology labs, bone metabolism research centers, orthopedic research departments, and gastrointestinal motility researchers.

Frequently Asked Questions